3,4-二氢-1,3-苯并恶嗪-2-酮 | 1125-85-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 3,4-二氢-1,3-苯并恶嗪-2-酮
• 英文名称: 3,4-dihydro-2H-benzo[e][1,3]oxazin-2-one
• 英文别名: 3,4-dihydro-2H-1,3-benzoxazin-2-one；4H-1,3-Benzoxazin-2(3H)-one；3,4-dihydro-benzo[e][1,3]oxazin-2-one；3,4-dihydro-benz[e][1,3]oxazin-2-one；3,4-Dihydro-benz[e][1,3]oxazin-2-on；2H-3,4-dihydro-1,3-benzoxazin-2-on；3,4-Dihydro-1,3-benzoxazin-2-one
• CAS: 1125-85-5
• 化学式: C₈H₇NO₂
• mdl: MFCD02313739
• 分子量: 149.149
• InChiKey: OOYREISBUILOLV-UHFFFAOYSA-N

物化性质

• 熔点：
  188 °C
• 沸点：
  160-165 °C(Press: 0.41 Torr)
• 密度：
  1.244±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3,4-Dihydro-1,3-benzoxazin-2-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3,4-Dihydro-1,3-benzoxazin-2-one
CAS number: 1125-85-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7NO2
Molecular weight: 149.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,4-二氢-1,3-苯并恶嗪-2-酮 在 氯磺酸 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 3-methyl-2-oxo-3,4-dihydro-2H-1,3-benzoxazine-6-sulfonyl chloride
  参考文献：
  名称：

  [EN] BICYCLIC PKM2 ACTIVATORS
  [FR] ACTIVATEURS BICYCLIQUES DE PKM2

  摘要：

  本文描述了包含激活丙酮酸激酶M2（PKM2）的化合物和组合物，其中化合物包括式（I）。本文还描述了利用激活PKM2的化合物治疗癌症的方法。

  公开号：

  WO2012088314A1
• 作为产物：
  描述：

  (2-hydroxy-phenyl)-acetyl azide 在 苯 作用下， 生成 3,4-二氢-1,3-苯并恶嗪-2-酮
  参考文献：
  名称：

  Lindemann; Schultheis, Justus Liebigs Annalen der Chemie, 1928, vol. 464, p. 246

  摘要：

  DOI：

文献信息

• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160031908A1

  公开（公告）日：2016-02-04

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。
• [DE] NEUE LANG WIRKSAME BETA-2-AGONISTEN, UND DEREN VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS<br/>[FR] NOUVEAUX BETA-2 AGONISTES A EFFET PROLONGE ET LEUR UTILISATION COMME MEDICAMENTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2005070908A1

  公开（公告）日：2005-08-04

  Die vorliegende Erfindung betrifft Verbindungen der Formel (1), worin die Gruppen X, Ra, Rb, R1, R1', R2, R2', R2'', R2''', V und n die in den Ansprüchen und in der Beschreibung genannten Bedeutungen haben können, sowie deren Verwendung als Arzneimittel, insbesondere zur Behandlung von entzündlichen und obstruktiven Atemwegserkrankungen.

  本发明涉及式(1)的化合物，其中X、Ra、Rb、R1、R1'、R2、R2'、R2''、R2'''、V和n可以是权利要求和说明书中所指的含义，以及它们用作药物，尤其是用于治疗炎性和阻塞性呼吸道疾病。
• ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS
  申请人：Controlled Chemicals, Inc.

  公开号：US20150175540A1

  公开（公告）日：2015-06-25

  Compounds having an isoindolin-1-one backbone of Formula (I) are disclosed which have utility in treating and/or preventing microbial infections, tumor growth, metastasis and other macrophage migration inhibitory factor (MIF)-modulated pathological conditions. Pharmaceutical compositions and methods and use of compounds of Formula (I) are also disclosed.

  公开了具有式(I)的异吲哚啉-1-酮骨架的化合物，其在治疗和/或预防微生物感染、肿瘤生长、转移以及其他巨噬细胞迁移抑制因子（MIF）调节的病理条件方面具有用途。还公开了式(I)化合物的药物组合物、方法和用途。
• New long acting beta-2-agonists and their use as medicaments
  申请人：Bouyssou Thierry

  公开号：US20050227975A1

  公开（公告）日：2005-10-13

  The present invention relates to compounds of formula 1 wherein the groups X, R a , R b , R 1 , R 1′ , R 2 , R 2′ , R 2″ , R 2′″ , V and n may have the meanings given in the claims and in the specification, and the use thereof as pharmaceutical compositions, particularly for the treatment of inflammatory and obstructive respiratory complaints.

  本发明涉及公式1的化合物，其中X、Ra、Rb、R1、R1′、R2、R2′、R2″、R2′″、V和n的含义如权利要求和说明书中所述，以及它们作为药物组合物的用途，特别是用于治疗炎性和阻塞性呼吸道疾病。
• Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
  申请人：KONETZKI Ingo

  公开号：US20070037781A1

  公开（公告）日：2007-02-15

  Disclosed are medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 wherein the groups X, R a , R b , R 1 , R 1′ , R 2 , R 2′ , R 2″ , R 2′″ , V and n may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

  公开了药物组合物，除了一个或多个，最好是1个，通用公式1中的化合物之外，还包括至少一个其他活性物质2，其中X，Ra，Rb，R1，R1′，R2，R2′，R2″，R2′″，V和n的含义如权利要求和说明书中所述，以及它们的制备方法和作为药物组合物用途。